AGMB Aligns With FDA
Agomab Therapeutics aligns with FDA on design of Phase 2b NOV-ERA study with Ontunisertib
Agomab Therapeutics Aligns With FDA On Design Of Phase 2b NOV-ERA Study With Ontunisertib;=
Agomab Therapeutics aligns with FDA on design of Phase 2b NOV-ERA study with Ontunisertib
Agomab Therapeutics Aligns With FDA On Design Of Phase 2b NOV-ERA Study With Ontunisertib;=